Clodronate treatment resulted in the reduction of infiltrating CD8+ T cells likely contributing to further protection against hepatocellular injury as increased portal CD8+ T cells has been observed in patients with NASH[39]. Here, CD8A is linked to metabolic dysfunction-associated steatohepatitis.